Willingness to pay for complete symptom relief of gastroesophageal reflux disease

被引:50
作者
Kleinman, L
McIntosh, E
Ryan, M
Schmier, J
Crawley, J
Locke, GR
de Lissovoy, G
机构
[1] MEDTAP Int, Bethesda, MD USA
[2] Univ Oxford, Hlth Econ Res Ctr, Oxford, England
[3] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland
[4] AstraZeneca LP, Wayne, PA USA
[5] Mayo Clin, Rochester, MN USA
关键词
D O I
10.1001/archinte.162.12.1361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Over $6 billion per year is spent on prescription medication for gastroesophageal reflux disease (GERD). This study is an economic analysis of patients' willingness to pay for a prescription medication that offers complete relief of GERD symptoms. Methods: The study was a cross-sectional, nonrandomized design recruiting patients from 5 clinical sites. A computer-administered discrete-choice questionnaire was used to explore patients' willingness to pay for various attributes (time to relief, amount of relief, side effects, and out-of-pocket cost) associated with GERD treatment. Patients chose between 2 different combinations of attributes by indicating which scenario they preferred. Data were gathered on health status, health-related quality of life, and sociodemographic characteristics. Results: Two hundred five patients completed the discrete-choice questionnaire with a consistency rate of 99.5%. All attributes were relevant to patient decision making, Respondents were willing to pay up to $182 to obtain complete relief in a short period of time without side effects. Patients with less severe GERD symptoms were willing to pay more to avoid side effects ($58.25 vs $38.43). Older patients were less willing to pay for better relief than younger patients. Conclusions: Results demonstrate that patients are willing to pay more per month for a medication that provides more complete and faster relief from GERD symptoms. This information can guide clinicians and formulary committees in evaluating optimal treatment for GERD.
引用
收藏
页码:1361 / 1366
页数:6
相关论文
共 40 条
[1]  
American Gastroenterological Association, 2001, BURD GASTR DIS
[2]   Willingness to pay as a measure of health benefits [J].
Bala, MV ;
Mauskopf, JA ;
Wood, LL .
PHARMACOECONOMICS, 1999, 15 (01) :9-18
[3]  
Bland M, 1995, INTRO MED STAT
[4]   Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma [J].
Blumenschein, K ;
Johannesson, M .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 80 (02) :189-194
[5]  
Bryan S, 1998, HEALTH ECON, V7, P595, DOI 10.1002/(SICI)1099-1050(1998110)7:7<595::AID-HEC381>3.3.CO
[6]  
2-5
[7]   Scaling back goals and recalibration of the affect system are processes in normal adaptive self-regulation: understanding 'response shift' phenomena [J].
Carver, CS ;
Scheier, MF .
SOCIAL SCIENCE & MEDICINE, 2000, 50 (12) :1715-1722
[8]   User preferences for computer administration of quality of life instruments [J].
Crawley, JA ;
Kleinman, L ;
Dominitz, J .
DRUG INFORMATION JOURNAL, 2000, 34 (01) :137-144
[9]   Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis [J].
Cross, MJ ;
March, LM ;
Lapsley, HM ;
Tribe, KL ;
Brnabic, AJM ;
Courtenay, BG ;
Brooks, PM .
RHEUMATOLOGY, 2000, 39 (11) :1242-1248
[10]   Using discrete choice modelling in priority setting: an application to clinical service developments [J].
Farrar, S ;
Ryan, M ;
Ross, D ;
Ludbrook, A .
SOCIAL SCIENCE & MEDICINE, 2000, 50 (01) :63-75